.Charles Baum, M.D., Ph.D., that supervised Mirati Rehabs' $ 5.8 billion purchase to Bristol Myers Squibb last year, is taking the reins of younger biotech Terremoto Biosciences.Baum's "considerable expertise in medication advancement, as well as established track record beforehand high-impact medications, will contribute," outbound CEO Peter Thompson, M.D., stated in a July 25 release. Thompson will keep his seat as board chairperson..Baum, a skilled physician-scientist, was actually the creator, president and chief executive officer of oncology-focused Mirati. Prior to that, he assisted create cancer medicines at Pfizer and also Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Currently, Baum will certainly act as chief executive officer at Terremoto, a provider developing small molecules to target disease-causing proteins-- like those discovered in malignant growth tissues-- using covalent connections. Existing treatments that use covalent bonds mainly target the amino acid cysteine. However, of the twenty amino acids that make up healthy proteins, cysteine is actually the minimum common. Terremoto is instead targeting some of the crucial amino acids, amino acid lysine, which is located in mostly all proteins.Through targeting lysine and various other amino acids, Terremoto plans to handle earlier undruggable conditions and also create first-in-class medications..The biotech, located in South San Francisco, raised $75 million in collection A funding in 2022. A little bit of much more than a year later on, the biotech more than doubled that variety in a $175 thousand set B.